Pay in 4 interest-free payments of $6.56 Learn more
Ships within 48 hours · Estimated delivery Aug 18 - Aug 23
Tirzepatide (Mounjaro for type 2 diabetes, Zepbound for weight management) is an FDA-approved dual GIP/GLP-1 receptor agonist that reduces appetite and slows gastric emptying
In the randomized double-blind controlled study STEP-1 (Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity), the treatment of adults with obesity once-weekly with semaglutide at a dose of 2.4 mg resulted in a mean reduction in body weight of approximately 15%, compared to 3% in the control group [7]
For those navigating their GLP-1 journey, SeekPeptides offers comprehensive resources including detailed protocol guides, GLP-1 progress tracking tools , and evidence-based information on optimizing treatment outcomes
In turn, this may lead to DNA damage in skin cells, causing serious sunburn or skin cancer
